Joanna Stanicka, Axonis Therapeutics CEO
October 30, 2024 06:00 AM EDT
Financing
Startups

Ax­o­nis snags $115M to test oral drugs for epilep­sy and neu­ro­path­ic pain

Kyle LaHucik

Senior Reporter

Boston biotech Ax­o­nis Ther­a­peu­tics has raised a $115 mil­lion Se­ries A to test whether its oral drug AXN-027 can help pa­tients with fo­cal epilep­sy and …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

Jazz wins ap­proval for bis­pe­cif­ic in bil­iary tract can­cer

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

At Jef­feries, all that man­u­fac­tur­ers want to talk about is GLP-1s

FDA ad­comm rais­es risk ques­tions on As­traZeneca’s An­dexxa

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times